DDO3602
DDO3602 is a PARP1 HEMTAC degradation agent mediated by HSP90. DDO3602 has good anti-tumor activity and tumor selectivity. DDO3602 induces G2/M phase arrest, DNA damage, and inhibits cell migration by degrading PARP1 in MCF-7 cells (IC50 = 187 nM). DDO3602 can be used for research on cancer such as breast cancer. (Pink: PARP1 Ligand ; Blue: HSP90 Ligand (HY-179203) ; Black: Linker (HY-W015300) )
Product Specifications
UNSPSC
12352005
Target
HSP; PARP; PROTACs
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; PROTAC
Field of Research
Cancer
Smiles
CC(C1=C(C=C(C(C(N2CC3=C(C2)C=CC(CN4CCN(CC4)C(CCCCCCC(N5CCN(C(C6=CC(CC7=NNC(C8=CC=CC=C87)=O)=CC=C6F)=O)CC5)=O)=O)=C3)=O)=C1)O)O)C
Molecular Formula
C51H58FN7O7
Molecular Weight
900.05
References & Citations
[1]Liu W, et al. HSP90 Mediates Targeted Degradation of Nonclient Protein PARP1 for Breast Cancer Treatment. J Med Chem. 2025 Oct 9;68 (19) :19933-19954.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940669-100 1x 100 µL
P27 / KIP1 (SX53G8), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC741231-100 1x 100 µL
Eosinophil Peroxidase (AHE-1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471931-100 1x 100 µL
CD3e (T-Cell Marker) (C3e/1931), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470965-500 1x 500 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details